Assessment of major gaps

Dec 19, 2019

Assessment of major gaps from the perspective of patients, patient advocates and NET health care professionals.

Due to the increasing incidence and prevalence of neuroendocrine tumors (NETs), there is a need to assess any gaps in awareness and care. A survey was undertaken in 2017 to identify perceived unmet needs from the perspectives of patients/families, patient advocates and health care professionals (HCPs). The survey consisted of 33–37 questions (depending on type of respondent) across four areas: information, care, treatments and research.

Recent News

Mounjaro® (Tirzepatide) & Neuroendocrine Cancers

Mounjaro® (Tirzepatide) & Neuroendocrine Cancers

We have had a number of enquiries about the use of Mounjaro® (Tirzepatide) and similar medications (e.g. Wegovy®, etc) in individuals with neuroendocrine cancer. Here we provide a summary of information currently available, which we hope will address some of the...

read more
URGENT UPDATE 9TH JULY – Rare Cancers Bill

URGENT UPDATE 9TH JULY – Rare Cancers Bill

Update 11th July 2025 Delighted to see Dr Scott Arthur's Rare Cancers Bill pass through third reading in the House of Commons on Friday. This Bill is a crucial step forward for those living with rare and less common cancers. Thank You to everyone who contacted their...

read more
URGENT ACTION NEEDED – CHANGES TO PIP PROPOSED

URGENT ACTION NEEDED – CHANGES TO PIP PROPOSED

URGENT ACTION NEEDED  The impact of cancer is far more than medical. With it, comes a hidden and often devastating financial burden that many do not see or expect: the ripple effect extending to family members and carers. From travelling to receive the right treatment...

read more